Company profile
Adaptive Biotechnologies Corporation
NASDAQ: ADPT · Healthcare · Biotechnology
#257 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
68BFH 66DQ 69GM 70SS 69
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$295.4M
Rev growth YoY (TTM)
+55.9%
Net income (FY)
-$59.5M
Employees
624
as of 2026-08-08
Market cap
$4.0B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$277.0M$277.0M2025
Net income-$59.5M-$59.5M2025
Operating income-$57.1M-$57.1M2025
Total assets$512.7M$512.7M2025
Liabilities$287.7M$287.7M2025
Equity$218.8M$218.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2021
By product
Sequencing Revenue51%
Development Support Revenue42%
Development Revenue Regulatory Milestones6%
By geography
Not disclosed.
The read
What is Adaptive Biotechnologies Corporation’s revenue?
Adaptive Biotechnologies Corporation booked $277.0M in FY2025 revenue, growing 55% year over year — faster than most Healthcare companies we track, at a -21.5% net margin.
Peers · Healthcare
AngioDynamics, Inc.72BXeris Biopharma Holdings, Inc.64CAurinia Pharmaceuticals Inc.78B+Vericel Corporation82B+Harrow Health, Inc.73BViemed Healthcare, Inc.75B+Neighbors
King →Key facts
CEOChad Robins
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeNASDAQ: ADPT
Employees624
IPO date2019-06-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.